Literature DB >> 26856825

Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014.

Helio S Sader1, Robert K Flamm2, Rodrigo E Mendes2, David J Farrell2, Ronald N Jones2.   

Abstract

We evaluated the antimicrobial susceptibility of 1,454 organisms consecutively collected from patients with bacteremia associated with skin and skin structure infections. The most common organisms obtained wereStaphylococcus aureus(670 organisms [46.1%]),Escherichia coli(200 organisms [13.8%]), β-hemolytic streptococci (βHS) (138 organisms [9.5%]), andKlebsiella pneumoniae(109 organisms [7.5%]). The susceptibility rates for ceftaroline were 97.9% forS. aureus(95.9% among methicillin-resistantS. aureus[MRSA]), 100.0% for βHS, 86.5% forE. coli, and 89.0% forK. pneumoniae Ceftaroline and tigecycline provided the best overall coverage.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26856825      PMCID: PMC4808146          DOI: 10.1128/AAC.02794-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Implementation of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in Routine Clinical Laboratories Improves Identification of Coagulase-Negative Staphylococci and Reveals the Pathogenic Role of Staphylococcus lugdunensis.

Authors:  Xavier Argemi; Philippe Riegel; Thierry Lavigne; Nicolas Lefebvre; Nicolas Grandpré; Yves Hansmann; Benoit Jaulhac; Gilles Prévost; Frédéric Schramm
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

2.  Microbial etiology and antimicrobial resistance in healthcare-associated versus community-acquired and hospital-acquired bloodstream infection in a tertiary care hospital.

Authors:  Liesbet De Bus; Gwen Coessens; Jerina Boelens; Geert Claeys; Johan Decruyenaere; Pieter Depuydt
Journal:  Diagn Microbiol Infect Dis       Date:  2013-09-26       Impact factor: 2.803

3.  Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.

Authors:  Helio S Sader; Robert K Flamm; Jennifer M Streit; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 4.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

5.  Trends in sources of meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia: data from the national mandatory surveillance of MRSA bacteraemia in England, 2006-2009.

Authors:  J Wilson; R Guy; S Elgohari; E Sheridan; J Davies; T Lamagni; A Pearson
Journal:  J Hosp Infect       Date:  2011-07-20       Impact factor: 3.926

Review 6.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

7.  National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011.

Authors:  Raymund Dantes; Yi Mu; Ruth Belflower; Deborah Aragon; Ghinwa Dumyati; Lee H Harrison; Fernanda C Lessa; Ruth Lynfield; Joelle Nadle; Susan Petit; Susan M Ray; William Schaffner; John Townes; Scott Fridkin
Journal:  JAMA Intern Med       Date:  2013-11-25       Impact factor: 21.873

Review 8.  Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review.

Authors:  S Chira; L G Miller
Journal:  Epidemiol Infect       Date:  2009-08-03       Impact factor: 2.451

9.  Staphylococcus lugdunensis, a common cause of skin and soft tissue infections in the community.

Authors:  Sidsel Böcher; Birgitte Tønning; Robert L Skov; Jørgen Prag
Journal:  J Clin Microbiol       Date:  2009-02-25       Impact factor: 5.948

10.  Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia.

Authors:  Jose A Vazquez; Christy R Maggiore; Phillip Cole; Alexander Smith; Alena Jandourek; H David Friedland
Journal:  Infect Dis Clin Pract (Baltim Md)       Date:  2015-01
View more
  4 in total

1.  In Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977).

Authors:  Ryuta Kishii; Yuko Yamaguchi; Masaya Takei
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 2.  The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Zahra Chegini; Alex van Belkum; Mehdi Mirzaii; Seyed Sajjad Khoramrooz; Davood Darban-Sarokhalil
Journal:  Antimicrob Resist Infect Control       Date:  2020-04-22       Impact factor: 4.887

3.  In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.

Authors:  Peiyao Jia; Ying Zhu; Hui Zhang; Bin Cheng; Ping Guo; Yingchun Xu; Qiwen Yang
Journal:  BMC Microbiol       Date:  2022-10-01       Impact factor: 4.465

4.  Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016).

Authors:  Hui Zhang; Yingchun Xu; Peiyao Jia; Ying Zhu; Ge Zhang; Jingjia Zhang; Simeng Duan; Wei Kang; Tong Wang; Ran Jing; Jingwei Cheng; Yali Liu; Qiwen Yang
Journal:  Antimicrob Resist Infect Control       Date:  2020-10-27       Impact factor: 4.887

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.